Skip to content

US · VALN · BIOTECHNOLOGY

Valneva SE (VALN) intrinsic value and stock valuation

$5.16as of 2026-11-21 · Mkt cap 495.93M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Valneva SE DCF and intrinsic value

InvestorsCraft values VALN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VALN’s statements →

Valneva SE Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Saint-Herblain, GE 44800 valneva.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$174.7M+9.6% 5y CAGRd
20112025
Net income
-$-115.19M
20112025
Free cash flow
-$-57.38M
20112025
Total equity
$106.2M+6.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$174.7M$169.6M$153.7M$361.3M$348.1M
Operating income-$-81.63M$13.3M-$-82.09M-$-113.44M-$-61.39M
Net income-$-115.19M-$-12.25M-$-101.43M-$-143.28M-$-73.42M
EPSd-$-1.37M-$-174.35K-$-1.46M-$-2.48M-$-1.5M
Operating cash flow-$-52.89M-$-67.22M-$-202.74M-$-245.34M$76.9M
Capital expenditure-$-4.48M-$-16.44M-$-14.31M-$-29.32M-$-93.17M
Free cash flow-$-57.38M-$-83.66M-$-217.06M-$-274.67M-$-16.27M
Total assets$398.8M$500M$460.1M$621.3M$817.4M
Total debt$207.3M$216.3M$208.8M$152.4M$114.7M
Net debt$97.6M$48M$82.7M-$-137.05M-$-231.99M
Total equity$106.2M$181.3M$128.3M$219.8M$170.6M
Cash and short-term investments$109.7M$168.3M$126.1M$289.4M$346.6M
Income statement
20252024202320222021
Revenue$174.7M$169.6M$153.7M$361.3M$348.1M
Cost of revenue$107.1M$98.5M$100.9M$324.4M$187.9M
Gross profit$67.5M$71M$52.8M$36.9M$160.2M
Research and development expenses$85.3M$74.1M$59.9M$104.9M$173.3M
Selling, general and administrative expenses$74.7M$95.1M$96.6M$57.6M$71.3M
Other expenses-$-10.83M-$-111.54M-$-21.52M-$-12.2M-$-22.98M
Operating expenses$149.2M$57.7M$134.9M$150.3M$221.6M
Cost and expenses$256.3M$156.3M$235.8M$474.8M$409.5M
Interest income$1.8M$2.36M$1.21M$260K$250K
Interest expense$41.9M$24M$23.3M$19.1M$17M
Depreciation and amortization$21.8M$19.6M$17.6M$21M$14.3M
Ebitda-$-50.47M$32.1M-$-57.72M-$-104.72M-$-38.73M
Operating income-$-81.63M$13.3M-$-82.09M-$-113.44M-$-61.39M
Total other income/expenses, net-$-32.49M-$-24.82M-$-16.54M-$-31.37M-$-8.59M
Income before tax-$-114.12M-$-11.49M-$-98.63M-$-144.81M-$-69.98M
Income tax expense$1.07M$760K$2.8M-$-1.54M$3.45M
Net income-$-115.19M-$-12.25M-$-101.43M-$-143.28M-$-73.42M
Weighted average shares outstanding$84.1M$70.3M$69.5M$57.7M$48.8M
Weighted average diluted shares outstanding$84.1M$70.3M$69.3M$57.7M$48.8M
Balance sheet
20252024202320222021
Cash and short-term investments$109.7M$168.3M$126.1M$289.4M$346.6M
Net receivables$27.8M$35.2M$41.7M$23.9M$44M
Inventory$50.2M$53.7M$44.5M$35.1M$124.1M
Total current assets$222.5M$299M$262.8M$424.7M$585.8M
Property, plant and equipment, net$138M$158.1M$156.6M$154M$173.8M
Goodwill and intangible assets$22.4M$25.3M$25.6M$28.7M$32.7M
Long-term investments$0.00$0.00$0.00$0.00$2.12M
Total non-current assets$176.3M$201M$197.2M$196.7M$231.5M
Total assets$398.8M$500M$460.1M$621.3M$817.4M
Accounts payable$9.07M$12.6M$17.6M$14.5M$16M
Short-term debt$20.6M$23.4M$47M$37M$10.2M
Deferred revenue$430K$3.01M$5.7M$9.41M$124M
Total current liabilities$93.3M$114.6M$158.9M$277.4M$369M
Long-term debt$186.6M$193M$161.9M$115.4M$104.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$4.74M
Total non-current liabilities$199.3M$204.2M$173M$124.2M$277.8M
Capital lease obligations$28.1M$28.9M$32M$53.6M$56.8M
Total liabilities$292.7M$318.8M$331.8M$401.6M$646.8M
Common stock$26M$24.4M$20.8M$20.8M$15.8M
Retained earnings-$-679.12M-$-563.93M-$-551.68M-$-450.25M-$-306.97M
Accumulated other comprehensive income (loss)$40.7M$40.2M$65.7M$55.3M$52.5M
Total equity$106.2M$181.3M$128.3M$219.8M$170.6M
Total investments$0.00$0.00$0.00$0.00$2.12M
Total debt$207.3M$216.3M$208.8M$152.4M$114.7M
Net debt$97.6M$48M$82.7M-$-137.05M-$-231.99M
Cash flow statement
20252024202320222021
Net income-$-115.19M-$-12.25M-$-101.43M-$-143.28M-$-73.42M
Depreciation and amortization$21.8M$19.6M$17.6M$21M$14.3M
Stock-based compensation$9.53M$7.97M$5.11M-$-8.66M$14.5M
Change in working capital-$-150K-$-11.57M-$-145.06M-$-145.98M$36.1M
Accounts receivable$13.3M$15.7M-$-2.85M$12.4M-$-21.35M
Inventory$1.03M-$-6.8M-$-9.16M$84.2M-$-92.37M
Accounts payable$0.00$0.00-$-17.4M-$-14.05M$35.2M
Net cash provided by operating activities-$-52.89M-$-67.22M-$-202.74M-$-245.34M$76.9M
Investments in property, plant and equipment-$-4.42M-$-13.87M-$-14.23M-$-29.32M-$-93.17M
Acquisitions, net$0.00$0.00-$-10.95M$10K$0.00
Net cash used for investing activities-$-1.71M$76.9M-$-20.59M-$-29.05M-$-93.12M
Common stock issued$30M$0.00$0.00$189.8M$166.8M
Common stock repurchased$0.00$0.00-$-240K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-620K$30.7M$63.1M$215.1M$154.5M
Net change in cash-$-58.62M$42.2M-$-160.45M-$-57.21M$142.3M
Cash at end of period$109.7M$168.3M$126.1M$289.4M$346.7M
Operating cash flow-$-52.89M-$-67.22M-$-202.74M-$-245.34M$76.9M
Capital expenditure-$-4.48M-$-16.44M-$-14.31M-$-29.32M-$-93.17M
Free cash flow-$-57.38M-$-83.66M-$-217.06M-$-274.67M-$-16.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Valneva SE

        Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.

        CEO
        Thomas Lingelbach
        Employees
        674
        Beta
        1.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Valneva SE (VALN)?

        Valneva SE (VALN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VALN undervalued?

        VALN trades at a price of $5.16 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.